(Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Biologics Contract Development Market Size Study & Forecast, By Source, by Product Service, by Disease Indication and Regional Analysis, 2023-2030

Global Biologics Contract Development Market Size Study & Forecast, By...

Home / Categories / Healthcare
Global Biologics Contract Development Market Size Study & Forecast, By Source, by Product Service, by Disease Indication and Regional Analysis, 2023-2030
Global Biologics Contract Development Market...
Report Code

Publish Date

$ 4250/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 4950/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 5650/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global Biologics Contract Development Market is valued at approximately USD 6.08 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.5% over the forecast period 2023-2030. Biologics contract development refers to the outsourcing of development and manufacturing services for biologic drugs or therapies to contract development and manufacturing organizations (CDMOs) or contract research organizations (CROs). Biologics are complex molecules derived from living organisms, including proteins, antibodies, vaccines, and gene therapies. The rising adoption of advanced technology for biological production is acting as a catalyzing factor for market growth. Furthermore, increased drug development methods by pharmaceutical companies, increased drug approval rates by the Food and Drug Administration, increased use of targeted pharmacological therapies, and increased desire for personalized medication are some of the factors resulting in the increase in market growth.

In addition, the surging prevalence of diseases such as neurological illnesses, gynecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders are contributing to the market development across the globe. According to World Health Organization in 2022, cancer is one of the main causes of death worldwide, accounting for over 10 million deaths in 2020. According to Cancer Tomorrow predictions in 2020, approximately 19.3 million cancer cases were reported in 2020, with this figure anticipated to climb to 30.2 million by 2040. In such circumstances, healthcare CDMOs play an important role in patient care because many biopharma companies aspire to develop novel medicines or first-in-class products for illness treatment. Furthermore, an increase in the adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries, an increase in the number of collaborations, contracts, and mergers with local players to develop advanced biologic products, and an increase in the development of greater manufacturing flexibility in the biopharmaceutical sector is expected to provide lucrative opportunities for market growth over the forecasting period. However, the high cost of biologics production processes, as well as a lack of understanding about the usage of these products, limit the growth of the biologics contract development industry.

The key regions considered for the Global Biologics Contract Development Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to lead the market in 2021. Strategic collaborations and acquisitions, as well as growing demand for specialized testing services, are driving the market. The growth of contract development organizations (CDOs) can be attributed mostly to the region's increased clinical trial and outsourcing activity. Furthermore, the high prevalence of chronic diseases is substantial fostering the demand for clinical studies in this region. These factors drive market expansion. Asia Pacific is expected to be the fastest growing region during the forecast period, because of different regulatory organization adjustments to update clinical trial evaluation standards based on global needs, biotechnology businesses are investing in the Asia Pacific region.

Major market players included in this report are:
WuXi Biologics
Abzena Ltd
Fujifilm Diosynth Biotechnologies
KBI Biopharma, Inc.
AGC Biologics
Thermo Fisher Scientific Inc.
Curia Global, Inc.
Bionova Scientific, Inc.
BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)
Recent Developments in the Market:
In September 2020, Almac Group recently announced the beginning of a contract for testing and development services for biologics. The development and testing of new biologic products will benefit from this expansion.
In February 2020, Lake Pharma In., Inc. has announced the debut of combined chemistry and biologics services, for faster antibody-drug conjugates development solutions for the pharmaceutical and biotechnology sectors.
Global Biologics Contract Development Market Report Scope:
Historical Data: 2020 - 2021
Base Year for Estimation: 2022
Forecast period: 2023-2030
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Source, Product Services, Disease Indication, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Source:
By Product Service:
Cell Line Development
Process Development
By Disease Indication:
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
By Region:
North America
Asia Pacific
South Korea
Latin America
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa


500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES